一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Sonrotoclax；Zanubrutinib；Placebo，当前状态为招募中。登记地点显示中国北京、重庆、广州、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sonrotoclax；Zanubrutinib；Placebo · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Sun Yat Sen University Cancer Center · 广州
- Nanfang Hospital, Southern Medical University · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology · 武汉
- Jiangsu Province Hospital · 南京
- The Affiliated Hospital of Xuzhou Medical University · 徐州
- Jiangxi Cancer Hospital · 南昌
- Liaoning Cancer Hospital and Institute · 沈阳
- Shaanxi Provincial Peoples Hospital · 西安
- Linyi Cancer Hospital · 临沂
- The Affiliated Hospital of Qingdao University Branch West Coast · 青岛
- Fudan University Shanghai Cancer Center · 上海
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital · 成都
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan · 杭州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- * Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC)
- * Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis
- * Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator
- * Relapsed or refractory disease after the last line of therapy
- * Measurable disease defined as ≥ 1 nodal lesion that is \> 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is \> 1 cm in longest diameter
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- * Adequate organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06742996；登记信息更新于 2026-09-14。